Ayala Pharmaceuticals Inc (ADXS)

[tx_farmer]

Christopher Duke
Senior Vice President and Chief Operating Officer
Mr. Duke joined Advaxis in October 2016 as Senior Vice President and Chief Operating Officer. He brings more than 20 years of life sciences experience to the Advaxis team, and is responsible for leading operations with a focus on overseeing clinical development programs and managing early commercial planning activities. Prior to joining Advaxis, Mr. Duke was Vice President, Global Commercial Operations at Amicus Therapeutics, Inc. where he played a lead role in the build out of the international business to support the successful launch of Galafold™ (migalastat), which was granted full approval by the European Commission in 2016. Mr. Duke was one of the first employees at Amicus and held several leadership roles in program/alliance management, medical affairs and commercial planning for 10 years.

Mr. Duke also served as Executive Director, International Commercial Operations for NPS Pharma where he led several strategic business planning initiatives and helped to establish NPS International to support the ex-US commercialization of Revestive® (teduglutide) and Natpar® (rhPTH[1-84]). He received his MBA from the Wharton School, University of Pennsylvania, his MPH from the University of Medicine and Dentistry of New Jersey, and a Bachelor of Science in Chemical Engineering from Rutgers University.

He has ties to another fairly new hire but i am a couple of woodford reserve's too many to look that up. Solid hire from the get go and impressive background, imo.